 year 2026, which is weighted 30 percent, and (c) pipeline progress during the financial years 2024 –2026, which is weighted 30 percent. 
Dependent on the achievement of the performance conditions, the number of performance shares 
allocated to the participants after expiration of the vesting period may amount to between 0 and 120 percent of the PSP award.

Table 2 – Incentive plans (CEO) 
 
 
 
 
Name of director (position) 
 
 
 The main conditions of share option plans Information regarding the reported financial year1 
Opening balance During the year Closing balance 
1 
Name of plan 2 
Performance 
period 3 
Award date 4 
Vesting date 5 
End of retention 
period 6 
Exercise period 7 
Exercise price 
(SEK) 8 
Share options 
held at beginning 
of year 
 9 
Share options 
awarded 10 
Share options 
vested 2 11 
Share options 
subject to 
performance 
condition 12 
Share options 
awarded and 
unvested 13 
Share options 
subject to 
retention period 
Fredrik Tiberg (CEO) 
EOSOP2021/2024  e time of grant (SEK 581) multiplied by the number of PSP awards (4,000) 
 
 
Application of performance criteria 
 
The performance measures for the CEO’s variable cash remuneration are resolved annually by the 
board of directors and have been selected to deliver the company’s strategy and to encourage 
behavior which is in the long- term interest of the company. In the s election of performance 
measures, the strategic objectives, and short- term and long- term business priorities for 2024 have 
been considered. The non -financial performance measures further contribute to alignment with 
sustainability as well as the company values. 
 
In 2024, the CEO was entitled to a variable remuneration corresponding to a maximum of 60% of 
the annual fixed salary. Earned variable remuneration related to 2024 , due to be paid in 2025, 
amounted to 50.5 % of the fixed base salary, excluding vacation pay and company car, 
corresponding to KSEK 3,167. The variable remuneration for 2024 was based   for 2024 was based to 20% on financial 
targets and to 80% on targets related to corporate, business, and pharmaceutical development, and 
the outcome is detailed as below. 
 
 
Table 3 - Performance of the CEO in the reported financial year: variable cash remuneration 
 
Name of 
director 
(position) 1 
Description of the performance 
criteria 2 
Relative weighting of the performance 
criteria 3 
a) Measured performance 
b) Remuneration outcome 
 Financial development 2024 
related to Revenues and Profit 
before taxes 24% a) Total revenue 
MSEK 1,740 to 
1,860. 
Profit before 
taxes MSEK 
330 to 450. 
b) KSEK 763 
Fredrik 
Tiberg 
(CEO) 
 Corporate, business and 
pharmaceutical development 
2024 76% b) KSEK 2,404

Comparative information on the change of remuneration and company performance 
 
Table 4 – Change of remuneration and company performance over the last five reported financial 
years (RFY) (KSEK) 
 
 RFY-4 vs RFY -5 RFY-3 vs RFY -4 RFY-2 vs RFY-3 RFY-1 vs RFY -2 RFY vs RFY 